耐信

Previous studies showed improvement among the children who were administered Nexium.

之前的研究表明使用耐信的儿童症状得到改善。

The safety and efficacy of Nexium has not been established in children less than one year of age.

对于小于一岁的患者，耐信的安全性和有效性尚未得到证实。

The FDA approved Nexium on the basis of exploratory research demonstrating the drug´s effectiveness and safety for use with children.

FDA在探索性的研究基础上批准了耐信证明了儿童应用这一药物的有效性和安全性。

The most common adverse reactions in children treated with Nexium were headache, diarrhea, abdominal pain, nausea, gas, constipation, dry mouth and sleepiness.

对于儿童患者，在使用耐信治疗中，最常见的不良反应是头痛、腹泻、腹痛、恶心、嗳气、便秘、口干及疲倦。

Nexium is part of a class of drugs known as proton pump inhibitors (PPIs).

耐信是质子泵抑制剂（PPI）奥美拉唑的一种异构体。